Extended‐release guanfacine hydrochloride in 6–17‐year olds with ADHD: a randomised‐withdrawal maintenance of efficacy study
Jeffrey H. Newcorn(Mount Sinai Hospital), Brigitte Robertson(Takeda (United States)), Vanja Sikirica(Moderna Therapeutics (United States)), Josep Antoni Ramos‐Quiroga(Universitat Autònoma de Barcelona), A. G. Lyne(University of Manchester), Sasha Sreckovic, Michael Huß(Johannes Gutenberg University Mainz), Benoît Dutray(Centre hospitalier de Rouffach), Mats Johnson(Sahlgrenska University Hospital), Ralph Bloomfield(AstraZeneca (United Kingdom)), Judy van Stralen(Ontario Centre of Excellence for Child and Youth Mental Health), Valerie Harpin(Sheffield Children's NHS Foundation Trust)
Cited by 37
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Computerized Training of Working Memory in Children With ADHD-A Randomized, Controlled Trial
|Journal of the American Academy of Child & Adolescent Psychiatry|2005|2k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder
|Neuroscience & Biobehavioral Reviews|2021|1.4k
Attention-deficit/hyperactivity disorder
|Nature Reviews Disease Primers|2015|1.3k